



Press release

GLSV leads investment in Action Pharma A/S

Zug/Munich, 17 January 2008 – *Global Life Science Ventures (GLSV)* today announced that it has led a EUR 15 million Series D financing of Action Pharma A/S, a Danish biotech company dedicated to the discovery and development of novel drugs for the treatment of Type 2 diabetes, organ damage, and other diseases. The deal was signed before Christmas 2007 and also included Scandinavian Life Science Venture (SLS) as another new investor as well as existing investors InnovationsKapital from Sweden and Sunstone Capital and Inventure Capital from Denmark.

Action Pharma (www.actionpharma.com), founded in 2000 with facilities in Copenhagen and Aarhus, will use the new funds to further develop its pipeline of drug candidates, currently comprising seven projects with two in clinical development. The most advanced compound is AP214, for the prevention of organ damage associated with e.g. myocardial infarction or major cardiac surgery. Phase II clinical trials in an orphan drug indication will be initiated in the USA in the first half of 2008. The company's second clinical compound, AP1030, for the treatment of obesity-induced Type 2 diabetes, will complete initial Phase I clinical trials in the first quarter of 2008.

Kuno Jung, PhD, Principal at GLSV, commented, "Action Pharma has established an exciting portfolio of peptide and small molecule product candidates addressing important therapeutic areas with unmet medical needs. We believe the company's future prospects are excellent."

Hans Küpper, PhD, Partner at GLSV, added, "We are pleased to complement our portfolio with another investment in a company in advanced stages of clinical development. We were impressed with the company's strong pipeline and management team and have confidence in its ability to bring new medications to the market."

About Global Life Science Ventures

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Switzerland and Germany, GLSV is dedicated to supporting early-stage companies originating from universities, scientific institutions or industry, but also invests in selected later-stage companies, including buy-outs. The group currently advises and manages funds totaling more than €200 million. GLSV has now financed 34 innovative life science companies throughout Europe and the USA, thirteen of which have completed an exit through IPO, trade sale or M&A. Since 1996, GLSV has built up a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.



Global Life Science Ventures

Industry-born team – Proven track record – Global perspective

Switzerland

GLSV AG
Postplatz 1, P.O. 626
CH – 6301 Zug
Tel. +41 (0)41 727 1940
Fax +41 (0)41 727 1945

Germany

GLSV GmbH
Von-der-Tann-Strasse 3
D – 80539 Munich
Tel. +49 (0)89 288 151 0
Fax +49 (0)89 288 151 30

www.glsv-vc.com
mailbox@glsv-vc.com

For additional information, please contact:

Dynamics Group

Christophe Lamps or Jonathan Leighton
Tel. +41 (0)22 308 6222
Fax +41 (0)22 308 6236
E-Mail: cla@dynamicsgroup.ch
jle@dynamicsgroup.ch

MC Services (Germany)

Stefan Riedel
Tel. +49 (0)89 210 228 40
Fax +49 (0)89 210 228 88
E-Mail: stefan.riedel@mc-services.eu